Regarding the potential treatment of gynecological cancers through the modulation of the Hippo/YAP pathway, a study carried out in an in vivo breast cancer model (a xenograft breast cancer model) showed that phosphorylated YAP1/TAZ proteins were subject to nuclear exclusion and proteasomal degradation, such that the growth of ALT‐treated tumor cells was inhibited in both breast cancer study models, in vitro and in vivo, suggesting that alantolactone can be used to target the ROS‐YAP pathway driving tumor cell proliferation and so could be a potent antitumoral agent [137]. Here, YAP1 is linked to breast cancer.